RANCHO CORDOVA, Calif., Aug. 11, 2011 /PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a wholly-owned subsidiary of American Pacific Corporation (Nasdaq®: APFC), announced it has concluded an agreement with Chimerix, Inc. to validate at commercial scale the manufacturing process for the API in Chimerix's broad spectrum antiviral drug candidate, CMX001, which is being developed for the prevention and treatment of smallpox. Chimerix will provide the investigational drug product under a Prime Contract with the U.S. Government Agency BARDA (Biomedical Advanced Research and Development Authority). According to Kenneth I. Moch, President and Chief Executive Officer of Chimerix, "We look forward to working with AFC and BARDA to harness the full potential of CMX001 to address the biodefense threat represented by smallpox."
The validation campaign will be conducted in AFC's recently completed second semi-works unit. The unit is located within a secured perimeter (security-alarmed fencing, cameras, controlled personnel access) segment of AFC on the DoD-regulated campus of Aerojet/GenCorp in Rancho Cordova. "This facility offers a state of the art, remotely operated process plant which can safely run hydrogenations and hazardous chemical processes, while containing reactants and products with Occupational Exposure Limits (OELs) down to 0.5 µg/m3, combining two of the core strengths of AFC. Equipment consists of 4 reactors (from 300-750 gal) and one 2.0 m2 Hastelloy filter-dryer. The unit is ideally suited for the production of APIs required by companies like Chimerix," stated Larry Zeagler, Executive Director of Product Management for AFC.
"This agreement further solidifies our position as a supplier with world class cGMP manufacturing capabilities in the United States. AFC is committed to maintaining the domestic assets and services needed by our customers to provide materials of critical importa
|SOURCE American Pacific Corporation|
Copyright©2010 PR Newswire.
All rights reserved